TNXP
Tonix Pharmaceuticals Holding Corp (TNXP)
Healthcare • NASDAQ • $14.09+3.45%
- Symbol
- TNXP
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $14.09
- Daily Change
- +3.45%
- Market Cap
- $200.15M
- Trailing P/E
- N/A
- Forward P/E
- -1.82
- 52W High
- $69.97
- 52W Low
- $11.60
- Analyst Target
- $46.25
- Dividend Yield
- N/A
- Beta
- 1.69
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to …
Company websiteResearch TNXP on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.